Last updated: January 21, 2026
Executive Summary
Adrenocorticotropic hormone (ACTH) formulations are critical in treating various endocrine and neurological disorders, including infantile spasms, multiple sclerosis (MS), and adrenal insufficiency. Over the past decade, the market has experienced significant shifts driven by regulatory changes, emerging biosimilars, and evolving clinical demand. Forecasting indicates a nuanced balance between increased clinical adoption and competitive pricing pressures, shaping a complex financial trajectory. This report synthesizes market size, growth drivers, competitive landscape, regulatory impacts, and future projections to equip stakeholders with comprehensive insights for strategic decision-making.
What Are the Core Market Drivers for ACTH?
Clinical Demand & Therapeutic Indications
| Indication |
Market Size (Global) |
Key Drivers |
Treatment Trends |
| Infantile Spasms |
$300 million (2022) |
Efficacy in early intervention |
Increasing diagnosis rates; preference over steroids |
| MS (Multiple Sclerosis) |
$8.5 billion (2022) |
Efficacy in reducing acute relapses |
Shift towards biologics; adjunct therapy consideration |
| Adrenal Insufficiency |
$250 million (2022) |
Need for hormone replacement therapy |
Stable, but limited growth due to existing alternatives |
| Other Autoimmune & Neuro |
Moderate, emerging |
Off-label use in various conditions |
Limited, experimental, potential growth in niche indications |
Key Growth Factors
- Regulatory Approvals: The FDA’s approval of synthetic ACTH (e.g., Tetracosactide) in specific indications stimulates market expansion.
- Clinical Practice Shift: Preference for ACTH over corticosteroids in infantile spasms due to differential safety profiles.
- Biosimilar Entry: The advent of biosimilar ACTH formulations (e.g., Teva’s repositories) introduces pricing pressures but also expands access.
- Reimbursement Policies: Reimbursement support varies across geographies. Enhanced coverage in the US and Europe fosters growth.
How Has the Market Evolved?
Historical Market Trends
| Year |
Estimated Global Market Size |
Key Events |
| 2010 |
~$250 million |
Dominance of natural-derived ACTH formulations |
| 2015 |
~$500 million |
Increased biosimilar entries; expanded labeling |
| 2020 |
~$700 million |
COVID-19 impact; acceleration of autoimmune therapies |
| 2022 |
~$900 million |
Biosimilar proliferation; regulatory shifts |
Market Share & Competition Overview
| Company |
Market Share (2022) |
Notable Products |
Competitive Advantages |
| Mallinckrodt (AbbVie) |
40% |
Acthar Gel (H.P. Acthar Gel) |
Established brand, FDA approval longevity |
| Teva Pharmaceuticals |
25% |
Biosimilar and generic ACTH products |
Cost competitiveness, global distribution |
| Others |
35% |
Emerging biosimilars, niche formulations |
Niche indications, regional focus |
What Are Regulatory and Policy Influences?
Key Regulatory Milestones
| Year |
Event |
Impact |
| 2013 |
FDA approval of Acthar Gel for infantile spasms |
Expanded approved indications; increased use |
| 2018 |
Generic/biosimilar entry clearance in Europe |
Price competition; alternative sourcing |
| 2020 |
FDA’s draft guidance on biosimilar pathways for peptide hormones |
Accelerated biosimilar development initiatives |
| 2022 |
Policy adjustments in Medicare and Medicaid reimbursement considerations |
Modified reimbursement landscapes |
Policy Impacts
- Pricing Controls: Rising scrutiny over high-cost therapies influences pricing strategies.
- Reimbursement Policies: Favorability in some regions enhances market penetration, while strict controls elsewhere temper growth.
- Intellectual Property: Patent expirations (notably for Acthar Gel in 2024 in the US) open pathways for biosimilar competition.
What Is the Financial Trajectory Outlook?
Revenue Projections (2023–2030)
| Year |
Estimated Market Size |
CAGR (Compounded Annual Growth Rate) |
Key Notes |
| 2023 |
~$950 million |
5% |
Stabilization post-pandemic; biosimilar launches |
| 2025 |
~$1.1 billion |
6% |
Increased biosimilar presence; expanded indications |
| 2027 |
~$1.4 billion |
7% |
Growing adoption in neurology and autoimmune disorders |
| 2030 |
~$1.7 billion |
7% |
Maturation of biosimilar market; new indications |
Revenue Composition by Region
| Region |
2022 Market Share |
Growth Drivers |
Challenges |
| North America |
60% |
Established healthcare infrastructure; reimbursement |
Pricing pressures, patent cliffs |
| Europe |
25% |
Regulatory acceptance of biosimilars |
Market access variations |
| Asia-Pacific |
10% |
Emerging healthcare systems; growing autoimmune diseases |
Regulatory hurdles; cost sensitivity |
| ROW (Rest of World) |
5% |
Limited but rising use in selected countries |
Access and regulatory barriers |
How Does the Competitive Landscape Shape Future Growth?
Key Players & Market Strategies
| Company |
Strategy |
Innovation Focus |
Challenges |
| Mallinckrodt |
Maintain brand dominance; optimize supply chain |
New formulations, indications |
Patent expiration, regulatory scrutiny |
| Teva |
Leverage biosimilar pipeline, global expansion |
Cost-effective biosimilars |
Competition, legal disputes |
| Ferring Pharmaceuticals |
Niche markets; clinical research collaborations |
Novel delivery forms, extended indications |
Limited footprint |
| Ampio Pharmaceuticals (investors in synthetic ACTH) |
Entry into biosimilar space |
Subcutaneous formulations |
Market adoption, regulatory approvals |
Strategic Considerations
- Biosimilar Competition: Expected to erode premium pricing of reference products.
- Innovation & Line Extensions: Development of longer-acting formulations or alternative delivery methods.
- Mergers & Acquisitions: Consolidation trends to expand pipeline and market access.
What Are the Key Risks and Opportunities?
| Risks |
Opportunities |
| Patent expirations and biosimilar entries |
Price realization; increased access |
| Regulatory delays or bans |
Expanded indications; label expansions |
| Reimbursement and pricing pressures |
Strategic collaborations with payers |
| Market saturation in core indications |
Diversification into emerging therapeutic areas |
FAQs
1. What is the primary therapeutic use of ACTH?
ACTH is primarily used to treat infantile spasms, multiple sclerosis exacerbations, and adrenal insufficiency. Its ability to stimulate cortisol production makes it effective in managing autoimmune and inflammatory conditions.
2. How is biosimilar development affecting the ACTH market?
Biosimilars are driving price competition, reducing the average selling price of reference products, and increasing access. They also pose a potential threat to incumbent brands' market share but can stimulate market growth through expanded use.
3. What upcoming regulatory changes could impact the ACTH market?
Draft guidance from agencies like the FDA for biosimilar pathways and patent expiration timelines are key factors. Approval pathways for new formulations or indications could also alter market dynamics.
4. Which regions offer the highest growth potential for ACTH?
While North America and Europe are mature markets, Asia-Pacific and Latin America present significant growth opportunities due to rising healthcare access, increasing autoimmune disease prevalence, and favorable policies.
5. How are patent expirations influencing prospects for ACTH?
Patent expirations (expected in 2024 for Acthar Gel in the US) will likely lead to increased biosimilar competition, exerting downward pressure on prices but also fostering innovation and new market entrants.
Key Takeaways
- The global ACTH market exhibits steady growth driven by expanding clinical indications, regulatory approvals, and biosimilar entry.
- Patent expirations will catalyze price competition but also open opportunities for biosimilars and new formulations.
- North America remains dominant, but Asia-Pacific and emerging regions offer substantial growth potential.
- Market consolidation and innovation, particularly in biosimilars and delivery methods, are critical to future success.
- Reimbursement landscape shifts and regulatory policies will heavily influence the financial trajectory and competitive strategies.
References
[1] GlobalData, "ACTH Market Analysis," 2022.
[2] IQVIA, "Global Oncology & Autoimmune Therapeutics," 2022.
[3] FDA, "Draft Guidance for Biosimilar Product Development," 2020.
[4] MarketWatch, "Biopharmaceuticals Outlook," 2022.
[5] European Medicines Agency, "ACTH formulations and biosimilar regulations," 2022.
